BioStock: Scandion Oncology’s COO previews key upcoming clinical milestones

Last month, Scandion Oncology took an important step in its transformation from early-stage biotech to a mature clinical stage company by appointing Maj Hedtjärn as new COO and Head of R&D operations. Hedtjärn is the latest addition to the company’s executive leadership team, and her extensive experience within R&D operations is an excellent fit for Scandion Oncology, which is aiming to build value as a clinical stage company. BioStock reached out to Hedtjärn to ask her about her role at Scandion Oncology and her vision at the company.

Read the full interview with Maj Hedtjärn at biostock.se:

https://www.biostock.se/en/scandion-oncologys-coo-previews-key-upcoming-clinical-milestones/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se